Comparison of pre- and post-RTX CT scan score and PFT measurements comparing averages at baseline and 1 year with the average individual change (p value) in subjects with repeat RTX dosing versus subjects with a 1-time RTX dose. Values are mean ± SD or n (%) unless otherwise specified.
| Variables | Repeat RTX Dosing, n = 17 | One-time RTX Dosing, n = 8 | ||
|---|---|---|---|---|
| Baseline | 1-yr Followup | Baseline | 1-yr Followup | |
| CT scan | n = 5 | n = 3 | ||
| Average score | 171 ± 42 | 152 ± 40 | 211 ± 79 | 244 ± 39 |
| Paired average Δ (p value)* | −22.9 (0.31) | 32.8 (0.50) | ||
| Improved/Stable** | 2/3 (100) | 0/2 (67) | ||
| Failure*** | 0 (0) | 1 (33) | ||
| PFT | ||||
| FVC | n = 14 | n = 5 | ||
| FVC, % predicted | 54 ± 14 | 63 ± 20 | 64 ± 15 | 52 ± 17 |
| Paired average Δ (p value) | +9.3 (0.0077) | −11.8 (0.13) | ||
| Improved/Stable** | 8/5 (93) | 0/2 (40) | ||
| Failure*** | 1 (7) | 3 (60) | ||
| TLC | n = 6 | n = 1 | ||
| TLC, % predicted | 53 ± 13 | 62 ± 14 | 70 | 77 |
| Paired average Δ (p value) | +8.5 (0.031) | NA | ||
| DLCO | n = 12 | n = 5 | ||
| DLCO, % predicted | 38 ± 12 | 39 ± 18 | 43 ± 16 | 29 ± 8 |
| Paired average Δ (p value) | +1.2 (0.59) | −14.2 (0.13) | ||
↵* Paired average Δ represents difference in the mean of paired observations with the p value as calculated using the Wilcoxon signed-rank test. A p value of < 0.05 was considered statistically significant.
↵** Improved is defined by > 10% decrease in CT score or > 10% improvement in FVC. Stable is defined by < 10% decrease but < 10% increase in CT score, or < 10% increase but < 10% decline in FVC (PIOPED criteria).
↵*** Failure is defined by a > 10% increase in CT score or a > 10% decline in FVC. Values are compared to baseline timepoint. RTX: rituximab; CT: computed tomography; PFT: pulmonary function tests; FVC: forced vital capacity; TLC: total lung capacity; NA: not applicable; PIOPED: pulmonary embolism diagnosis.